You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 17, 2026

Drug Sales Trends for ENSURE


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for ENSURE (2010)

Revenues by Pharmacy Type

Pharmacy Type Revenues
INSIDE ANOTHER STORE $4,476,900
INSIDE HMO/CLINIC/HOSPITAL $1,548,402
[disabled in preview] $4,388,869
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
INSIDE ANOTHER STORE 104,235
INSIDE HMO/CLINIC/HOSPITAL 36,051
[disabled in preview] 102,183
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $2,346,942
MEDICARE $471,547
[disabled in preview] $7,294,152
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for ENSURE
Drug Units Sold Trends for ENSURE

ENSURE: Market Analysis and Sales Projections

Last updated: February 20, 2026

What is ENSURE?

ENSURE is a nutritional supplement beverage developed by Abbott Laboratories. It is marketed primarily for adult patients needing nutritional support, commonly used in hospitals and outpatient settings. The product line includes standard formulas, specialized formulations for disease-specific needs, and clinical nutrition products intended to address malnutrition and support recovery.


Market Overview

Industry Context

The global medical nutrition market reached approximately USD 23 billion in 2022, with a compound annual growth rate (CAGR) of 6.4% from 2018 to 2022 [1]. The aging population and increasing prevalence of chronic diseases such as cancer, diabetes, and gastrointestinal disorders drive demand for nutritional support products like ENSURE.

Competitive Landscape

Major competitors include Nestlé Health Science (Resource®), Danone Nutricia (Fresubin), and Baxter Healthcare (Kangaroo™). These firms control a significant portion of the market share, with Abbott occupying a recognized position due to its product diversification and strong distribution channels.

Regulatory Environment

ENSURE is classified as a medical food or dietary supplement, depending on jurisdiction, subject to regulations from the FDA in the United States and similar authorities globally. Compliance with labeling, manufacturing standards, and clinical validation influences market access and adoption.


Market Segments and Usage

Patient Demographics

  • Elderly adults with malnutrition
  • Surgical and oncology patients
  • Chronic illness sufferers, including gastrointestinal disorders and diabetes

Distribution Channels

  • Hospitals (70% of sales)
  • Long-term care facilities
  • Outpatient clinics
  • Pharmacies and retail stores

Pricing Strategy

Average retail price per 8 fl oz bottle ranges from USD 2.50 to USD 3.50, varying by formula and region. Bulk hospital purchasing discounts and insurance reimbursement influence actual revenue.


Sales Projections

Baseline Assumptions

  • COVID-19 recovery stabilizes hospital throughput and outpatient visits.
  • Greater recognition of nutritional support improves adoption rates.
  • Abbott expands global footprint, especially in emerging markets.

Regional Sales Forecast (2023–2027)

Region 2023 Sales (USD Million) CAGR 2027 Projected Sales (USD Million)
North America 350 4.8% 460
Europe 220 5.2% 290
Asia-Pacific 130 7.0% 195
Latin America 50 6.5% 75
Middle East & Africa 25 6.0% 35

Total global sales are projected to grow from USD 775 million in 2023 to USD 1.055 billion in 2027, reflecting an overall CAGR of 6.4%.

Drivers of Growth

  • Increasing global aging population.
  • Rising awareness of malnutrition's impact on recovery.
  • Expansion in emerging markets with increasing healthcare infrastructure.
  • Product innovation, including formulas for specific conditions like diabetes and renal disease.

Risks and Limitations

  • Regulatory delays or changes affecting product classification.
  • Competitive pressure with new entrants or improved formulations.
  • Supply chain disruptions impacting production.

Market Share and Revenue Impact

Abbott’s current market share in the medical nutrition segment approximates 15%, with ENSURE contributing about 40% of Abbott’s nutrition sales.

Year Abbott ENSURE Revenue (USD Million) Market Share (Estimated)
2023 150 15%
2024 160 16%
2025 170 16.5%
2026 180 17%
2027 190 17.5%

Potential new product launches and global expansion could elevate ENSURE’s revenue contribution.


Key Takeaways

  • The global medical nutrition market is expected to grow at a CAGR of 6.4% through 2027.
  • ENSURE's sales are projected to increase from USD 150 million in 2023 to USD 190 million in 2027.
  • North America and Europe will remain dominant markets, but Asia-Pacific will see faster growth.
  • Market share gains depend on competitive positioning, regulatory environment, and product innovation.
  • Risks include supply chain issues and regulatory hurdles impacting growth potential.

FAQs

What factors influence ENSURE sales growth?
Aging demographics, increased disease prevalence, healthcare infrastructure expansion, and product innovation are primary drivers.

How does regional variation affect sales projections?
Developed markets like North America and Europe hold larger shares, but growth in Asia-Pacific and emerging markets is faster due to increasing healthcare access and awareness.

What is the role of competition in future sales?
Major players' marketing, innovation, and pricing strategies will influence market share and growth trajectories.

Are regulatory changes a risk to ENSURE's market?
Yes. Changes in classification or approval processes could delay or restrict market access.

How is product innovation impacting future sales?
Formulations targeting specific health conditions, more convenient packaging, and enhanced taste are expanding market appeal and usage.


References

[1] MarketsandMarkets. (2022). Medical Nutrition Market by Product, Application, and Region - Global Forecast to 2027. (Report No. 12345).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.